

Advanced Detection of Performance Enhancement (ADOPE):


Detecting gene doping with innovative targeted next generation sequencing

Alexander Armstrong, Nicole Bennis, Susan Bouwmeester, Lisa Büller, Kavish Kohabir, Monique de Leeuw, Venda Mangkusaputra, Jard Mattens, Janine Nijenhuis, Timothy Páez-Watson, Lisbeth Schmidtchen, Gemma van der Voort

TUDelft


On your marks, get set, **DETECT!**


Major concerns have risen around the misuse of gene editing techniques, particularly for human enhancement. An example of this misuse is gene doping, which is a big threat for fair sports. We developed a method to detect gene doping by targeted sequencing with our novel fusion protein: dxCas9-Tn5. We used EPO as a model gene.



Fusion Protein dxCas9-Tn5


Targeted library preparation relies on our innovative fusion protein consisting of a dxCas9 [3] and a Tn5 transposase[4] for sequencing.





We tested the fusion functionality in vitro and showed targeted adapter integration.

To cover all variations for the EPO gene, we modeled the extent of codon variation in a heat map and generated the corresponding **sgRNAs** targeting exon-exon junctions.^[5]



at each exon-exon junction in the human EPO gene.

Targeted Sequencing

MinION sequencing with a library prepared sample treated with our fusion

protein. We obtained 89 unique alignments to target EPO DNA and

Integrated Human Practices



Prof. Hidde Haisma - Gene and cell doping expert group WADA EPO as model gene

Dr. Olivier de Hon - Dutch Doping Authority High throughput prescreening





Prof. Paul Dimeo - Expert in drug use in sport and antidoping Anticipate athlete behavior

Hackathon Cyber Security Week Expanding database





Future of gene doping















A predictive EPO gene doping model to determine the detection time window and **sensitivity** for sample


preparation.[1]

artificial extracted EPO gene doping DNA at concentrations predicted by ourmodel. Samples proceed to prescreening.




throughput prescreening based on nanoparticles (d-AuNPs)[2].

We distinguished between on-target DNA probe for EPO gene (red) with offtarget DNA probe (purple).



0 alignments of non target DNA. Fig. 8. MinION device



of dxCas9 position (red arrow) and the addition of sequencing adapters (blue arrow).

Achievements

- Co-organized the first EurAsian Meetup in China with BGIC-Global.
- Modeled the time dependent concentration of EPO gene doping.
- Optimized a protocol for DNA extraction from blood serum to detect gene doping.
- Integrated a prescreening method based on gold nanoparticle stabilization.
- Designed, constructed, expressed and purified a novel dxCas9-Tn5 fusion protein.
- Developed software to generate barcodes and sgRNAs for gene doping detection with targeted sequencing.
- Demonstrated targeted integration by dxCas9-Tn5 for library preparation and targeted nanopore sequencing.
- Developed a software tool for sequencing data analysis.
- Constructed 13 biobricks, including dxCas9-Tn5, dxCas9 and Tn5 (BBa_K2643000-BBa_ K2643012).

[1] Ni W., et al. Gene Therapy. 2011, 18, 709-718. [2] Beatsen-Young A.M., et al. Biosensors and Bioelectronics, 2018, 29-36. [3] Hu, J.H., et al Nature, 2018, 556(7699),57. [4] Picelli, S., et al Genome research, 2014,177881. [5] Beiter T., et al. Gene Therapy. 2011, 18: 225-231.

Whole

blood



Fig. 3. Sample preparation and prescreening workflow.




Target

MADAC

Non target



XXXX







arbor biosciences









Come experience our laboratory in Virtual Reality at the Exhibition Space!



Plasma

DNA

Blood

plasma



DEPARTMENT OF SCIENCE EDUCATION &